Floatz logo

Tas-102

Iris Melanoma

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityunclassifiedPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Iris Melanoma cohort.

Asset / SponsorPhaseRating
Tyrosinase Peptide
National Cancer Institute (NCI)
Phase 3BB
FLUTICASONE
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BB
Sargramostim
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
Phase 2B

View all 32 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →